Report: Medicare Part D Pays Needlessly High Brand-Name Drug Prices Compared with Other Developed Countries and with U.S. Government Programs
Because of congressional restrictions on the government’s ability to negotiate with the pharmaceutical industry, Medicare Part D drug prices are significantly higher than those in either Medicaid or the Veterans Health Administration and 30 other countries, a study by Carleton University and Public Citizen finds.